Literature DB >> 33231275

Thiamine Pyrophosphokinase Deficiency due to Mutations in the TPK1 Gene: A Rare, Treatable Neurodegenerative Disorder.

Christina T Rüsch1, Saskia B Wortmann2,3,4, Reka Kovacs-Nagy2,5, Patrice Grehten6, Johannes Häberle7, Beatrice Latal8, Georg M Stettner1.   

Abstract

TPK deficiency due to TPK1 mutations is a rare neurodegenerative disorder, also known as thiamine metabolism dysfunction syndrome 5 (OMIM no.: 614458). Here, we report a new patient with compound heterozygous TPK1 mutations, of which one has not been described so far. The individual reported here suffered from acute onset encephalopathy, ataxia, muscle hypotonia, and regression of developmental milestones in early infancy, repeatedly triggered by febrile infections. Initiation of high-dose thiamine and magnesium supplementation led to a marked and sustained improvement of alertness, ataxia, and muscle tone within days. Contrary to the described natural history of patients with TPK deficiency, the disease course was favorable under thiamine treatment without deterioration or developmental regression during the follow-up period. TPK deficiency is a severe neurodegenerative disease. This case report demonstrates that this condition is potentially treatable. High-dose thiamine treatment should therefore be initiated immediately after diagnosis or even upon suspicion. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 33231275     DOI: 10.1055/s-0040-1715628

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  2 in total

Review 1.  Treatable Hyperkinetic Movement Disorders Not to Be Missed.

Authors:  Aurélie Méneret; Béatrice Garcin; Solène Frismand; Annie Lannuzel; Louise-Laure Mariani; Emmanuel Roze
Journal:  Front Neurol       Date:  2021-12-01       Impact factor: 4.003

2.  Case report of two affected siblings in a family with thiamine metabolism dysfunction syndrome 5: a rare, but treatable neurodegenerative disease.

Authors:  Xiaoyan Li; Zhixin Huang; Yong Chen; Xiaolan Sun; Zhaoshi Yi; Jihua Xie; Xiongying Yu; Hui Chen; Jianmin Zhong
Journal:  BMC Neurol       Date:  2022-09-29       Impact factor: 2.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.